<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68943">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068040</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD IRB 130398</org_study_id>
    <nct_id>NCT02068040</nct_id>
  </id_info>
  <brief_title>Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)</brief_title>
  <acronym>HFPEF</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major goal of this proposal is to characterize the ability of  epicatechin which a
      component of dark chocolate to improve the

        1. structural and functional features of skeletal muscle (SkM)

        2. exercise capacity (as assessed by VO2 max)

        3. parameters of diastolic heart function (as assessed by echocardiography)

      We propose that a 3  month treatment with epicatechin (through CocoaViaÂ® capsules) will lead
      to a significant improvement in exercise capacity and diastolic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Inclusion/Exclusion Criteria:

        1. New York Heart Association Class II/III  HF with preserved ejection fraction (EF) of
           &gt;50%.

        2. Nonsmokers

        3. Subject not taking Coumadin, Xarelto, Prasugrel or Pradaxa. Patients on Plavix for drug
           eluting stent will not be excluded.

        4. Ages between 40-65. We will exclude any women of child bearing potential
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in exercise capacity</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objectively evaluate exercise capacity through cycle ergometry to measure VO2 max</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in skeletal muscle metabolism</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in skeletal muscle metabolism will be evaluated by magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skeletal muscle biopsies and blood draws will be performed to obtain experimental samples</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CocoaVia capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CocoaVia</intervention_name>
    <description>CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol</description>
    <arm_group_label>CocoaVia capsules</arm_group_label>
    <other_name>Epicatechin consumption</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically Diagnosed Heart Failure with Ejection Fraction of &gt;55%

          -  BMI 27-32

          -  No Significant HbA1C fluctuations in past 6 months

        Exclusion Criteria:

          -  Smoking or quit smoking less than 1 year prior to enrollment

          -  Substance Abuse

          -  Taking Coudmadin or Pradaxa
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Minal V Patel</last_name>
    <phone>858-657-5354</phone>
    <email>chocolatestudy2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Patel</last_name>
      <phone>858-657-5354</phone>
    </contact>
    <investigator>
      <last_name>Pam Taub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb;5(1):43-7. doi: 10.1111/j.1752-8062.2011.00357.x. Epub 2011 Nov 7.</citation>
    <PMID>22376256</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Pam Taub, MD</investigator_full_name>
    <investigator_title>Dr. Pam Taub</investigator_title>
  </responsible_party>
  <keyword>with preserved ejection fraction of &gt;55%</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
